PREDNICEN-M

Clinical safety rating: caution

Comprehensive clinical and safety monograph for PREDNICEN-M (PREDNICEN-M).

How it works

Prednicen-M is a glucocorticoid that binds to the glucocorticoid receptor (GR), leading to altered gene expression. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses cytokine production (e.g., IL-1, IL-2, TNF-alpha). It also induces lipocortin synthesis, which inhibits arachidonic acid release.

What the body does with it

Metabolism	Metabolized in the liver via CYP3A4 (major) and other CYP enzymes. Prednicen-M is a prodrug of prednisolone.
Excretion	Renal: ~80% as metabolites and unchanged drug (primarily as 17-ketosteroids and glucuronide conjugates); fecal: <5%; biliary: minor.
Half-life	2-3 hours (prednisone); terminal half-life of prednisolone is 2-4 hours in normal renal function, prolonged to 3-4 hours in renal impairment, and may be extended in hepatic impairment.
Protein binding	Prednisolone: 70-90% bound to corticosteroid-binding globulin (CBG, transcortin) and albumin; prednisone: approximately 70% bound to CBG and albumin.
Volume of Distribution	0.5-1.2 L/kg (prednisolone); the high Vd indicates extensive tissue distribution, particularly to liver, kidney, and adipose tissue.
Bioavailability	Oral: 70-85% (prednisone is rapidly converted to prednisolone in liver; bioavailability is dose-dependent and slightly reduced by food).
Onset of Action	Oral: 1-2 hours (glucocorticoid effect); IV: within 1 hour; IM: 1-2 hours (assuming prednisone conversion to prednisolone).
Duration of Action	12-36 hours (pituitary-adrenal suppression lasting up to 36 hours); clinical duration of anti-inflammatory effects is 12-24 hours after single dose.

Classification & Brands

Dosing & administration

Oral, 5-60 mg/day divided every 6-12 hours, adjusted based on disease severity and response.

Dosage form	TABLET
Renal impairment	GFR ≥50 mL/min: no adjustment; GFR 10-49 mL/min: no adjustment; GFR <10 mL/min: no adjustment; hemodialysis: supplemental dose not required.
Liver impairment	Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: reduce dose by 75%.
Pediatric use	Oral, 0.14-2 mg/kg/day divided every 6-12 hours, maximum 60 mg/day.
Geriatric use	Start at lowest effective dose (e.g., 5 mg/day) and titrate slowly due to increased risk of osteoporosis, hypertension, and glucose intolerance.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for PREDNICEN-M (PREDNICEN-M).

Breastfeeding	Prednisolone (active metabolite) transfers into breast milk; M/P ratio 0.44-0.63. Infant dose ~0.1% of maternal weight-adjusted dose. High doses >40 mg/day: avoid breastfeeding for 4 hours after administration. Monitor infant for adrenal suppression.
Teratogenic Risk	First trimester: Increased risk of cleft palate (odds ratio 3.35). Second/third trimester: Fetal adrenal suppression, intrauterine growth restriction, oligohydramnios with prolonged use. Risk outweighs benefits unless maternal condition requires therapy.

Warnings & precautions

■ FDA Black Box Warning

No FDA black box warning specifically for Prednicen-M. However, corticosteroids in general carry warnings for immunosuppression, increased susceptibility to infections, and risk of adrenal suppression upon withdrawal.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Systemic fungal infections","Known hypersensitivity to prednisone or any component","Administration of live or live attenuated vaccines (relative)"]

Clinical Precautions

Precautions

["Adrenal suppression: Avoid abrupt withdrawal; taper dose.","Immunosuppression: Increased risk of infections; avoid live vaccines.","Osteoporosis: Long-term use may cause bone loss.","GI effects: Increased risk of peptic ulcers; use with caution in ulcerative colitis.","Ocular effects: May cause glaucoma or cataracts.","Fluid/electrolyte disturbances: May cause sodium retention, potassium loss.","Psychiatric effects: May cause mood swings, euphoria, or psychosis.","Children: May suppress growth.","Pregnancy: Fetal risk; weigh benefits vs risks."]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

PREDNICEN-M

Clinical safety rating: caution

Comprehensive clinical and safety monograph for PREDNICEN-M (PREDNICEN-M).

How it works

What the body does with it

Metabolism	Metabolized in the liver via CYP3A4 (major) and other CYP enzymes. Prednicen-M is a prodrug of prednisolone.
Excretion	Renal: ~80% as metabolites and unchanged drug (primarily as 17-ketosteroids and glucuronide conjugates); fecal: <5%; biliary: minor.
Half-life	2-3 hours (prednisone); terminal half-life of prednisolone is 2-4 hours in normal renal function, prolonged to 3-4 hours in renal impairment, and may be extended in hepatic impairment.
Protein binding	Prednisolone: 70-90% bound to corticosteroid-binding globulin (CBG, transcortin) and albumin; prednisone: approximately 70% bound to CBG and albumin.
Volume of Distribution	0.5-1.2 L/kg (prednisolone); the high Vd indicates extensive tissue distribution, particularly to liver, kidney, and adipose tissue.
Bioavailability	Oral: 70-85% (prednisone is rapidly converted to prednisolone in liver; bioavailability is dose-dependent and slightly reduced by food).
Onset of Action	Oral: 1-2 hours (glucocorticoid effect); IV: within 1 hour; IM: 1-2 hours (assuming prednisone conversion to prednisolone).
Duration of Action	12-36 hours (pituitary-adrenal suppression lasting up to 36 hours); clinical duration of anti-inflammatory effects is 12-24 hours after single dose.

Classification & Brands

Dosing & administration

Oral, 5-60 mg/day divided every 6-12 hours, adjusted based on disease severity and response.

Dosage form	TABLET
Renal impairment	GFR ≥50 mL/min: no adjustment; GFR 10-49 mL/min: no adjustment; GFR <10 mL/min: no adjustment; hemodialysis: supplemental dose not required.
Liver impairment	Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: reduce dose by 75%.
Pediatric use	Oral, 0.14-2 mg/kg/day divided every 6-12 hours, maximum 60 mg/day.
Geriatric use	Start at lowest effective dose (e.g., 5 mg/day) and titrate slowly due to increased risk of osteoporosis, hypertension, and glucose intolerance.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for PREDNICEN-M (PREDNICEN-M).

Breastfeeding	Prednisolone (active metabolite) transfers into breast milk; M/P ratio 0.44-0.63. Infant dose ~0.1% of maternal weight-adjusted dose. High doses >40 mg/day: avoid breastfeeding for 4 hours after administration. Monitor infant for adrenal suppression.
Teratogenic Risk	First trimester: Increased risk of cleft palate (odds ratio 3.35). Second/third trimester: Fetal adrenal suppression, intrauterine growth restriction, oligohydramnios with prolonged use. Risk outweighs benefits unless maternal condition requires therapy.

Warnings & precautions

■ FDA Black Box Warning

Side Effect Profile

Serious Effects

Absolute Contraindications

["Systemic fungal infections","Known hypersensitivity to prednisone or any component","Administration of live or live attenuated vaccines (relative)"]